The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Open accessAbstract
Inhibiting protein function selectively is a major goal of modern drug discovery. Here, we report a previously understudied benefit of small molecule proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases to target proteins for their ubiquitination and subsequent proteasome-mediated degradation. Using promiscuous CRBN- and VHL-recruiting PROTACs that bind >50 kinases, we show that only a subset of bound targets is degraded. The basis of this selectivity relies on protein-protein interactions between the E3 ubiquitin ligase and the target protein, as illustrated by engaged proteins that are not degraded as a result of unstable ternary complexes with PROTAC-recruited E3 ligases. In contrast, weak PROTAC:target protein affinity can be stabilized by high-affinity target:PROTAC:ligase trimer interactions, leading to efficient degradation. This study highlights design guidelines for generating potent PROTACs as well as possibilities for degrading undruggable proteins immune to traditional small-molecule inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, possible off-target effects may arise from the E3 ligase ligand side, such as the degradation of GSPT1 in this work and others[42–44].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [42]
In the citing paper
“In addition, Bondeson et al. showed that a promiscuous ligand for about 50 kinases could induce only a subset of its targets for degradation when converted into a PROTAC45.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [45]
In the citing paper
“Several mechanisms have been shown to contribute to this increase in selectivity. This includes steric incapability of some targets to form a productive ternary complex, or lack of a suitably positioned lysine residue for ubiquitination.62−69”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [65]
In the citing paper
“Multiple studies have reported that the stability of the E3-degrader-POI ternary complex may influence degradation kinetics and selectivity, and may be a more reliable predictor for degradation than target engagement alone (Bondeson et al., 2018; Roy et al., 2019).”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Bondeson et al., 2018
In the citing paper
“The propensity of different E3 ligases to ubiquitinate specific proteins has been reported to vary in the literature (Bondeson et al., 2018; Smith et al., 2019) and variation is attributed to the unique protein-protein interactions that may form between the E3 ligase and target.”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Bondeson et al., 2018
In the citing paper
“PROTACs are small molecules with two functional ends, wherein one end binds to the protein of interest while the other binds to an E3 ubiquitin ligase (2, 3), bringing the ubiquitin ligase to the target protein, leading to its ubiquitination and subsequent degradation by the proteasome.”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [2]
In the citing paper
“Addition of a linker with a moiety to recruit either VHL or CRBN reduced foretinib’s inhibition for several of these kinases, but overall both PROTACs retained broad non-selective inhibition.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“It has been shown that a PROTAC’s ability to bind the target protein is not the primary determinant of whether efficient degradation occurs; rather, it has been suggested that formation of the ternary complex is limiting (i.e., the ability of the PROTAC to simultaneously bind both the target protein and the E3 ligase) 20, 22.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“Moreover, the extent to which different kinases were degraded was not simply a reflection related to how tightly the PROTAC bound the kinase, since inhibition constants were not correlated with cellular degradation 20.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“Using a competitive binding assay, foretinib itself was first shown to inhibit at least a quarter of the human kinome 20.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“Remarkably, however, cellular treatment revealed that certain kinases were degraded much more efficiently by the VHL-recruiting PROTAC, while others were degraded more efficiently by the CRBN-recruiting PROTAC 20.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“It has further been shown that PROTAC selectivity does not necessarily mimic that of its target-binding warhead, but rather depends sensitively on the linker 20, 23, 24, 33”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“PROTACs may also benefit from cooperative PPIs between the E3 ligase and the POI. This can have the advantages of improved potency49 and selectivity50.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [49]
In the citing paper
“the pairing of VHL versus CRBN for a given target can result in different degradation efficiencies49, as was first observed when targeting the fusion oncogene BCR–ABL by PROTACs118.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [49]
In the citing paper
“In addition, many PROTACs are not completely selective and can degrade proteins other than their desired targets [7, 90, 204, 205].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [204]
In the citing paper
“A major advantage of VHL-based PROTACs is their target-specificity [44, 53].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [53]
In the citing paper
“high binary binding affinities are not necessarily needed to result in efficient degradation of a target protein [53]”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [53]
In the citing paper
“using the same promiscuous kinase inhibitor as a warhead, the CRBN-based PROTAC degrades more kinases than the VHL-based PROTAC [53].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [53]
In the citing paper
“and several PROTACs have been found to be more selective than the inhibitor from which they were derived 12,28,29,30 ,”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Self-citationA quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,923
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. J. W. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,867
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 965
Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer
Torres‐Ayuso, P., & Brognard, J. (2022) · Molecular Pharmacology · doi:10.1124/molpharm.121.000306 · Cited by 15
Pan, Y., Wang, Y., & Gou, S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108491 · Cited by 18
Weldert, A. C., Frey, A. F., Krone, M. W., Krähe, F., Kuhn, H., Kersten, C., & Barthels, F. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00359h · Cited by 16
Nalawansha, D. A., Mazis, G., Husemoen, G., Ashton, K. S., Deng, W., Wurz, R. P., Tran, A. T., Lanman, B. A., Xie, J., Guenette, R. G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63128-4 · Cited by 15
Recent advances in targeting protein degradation for tumor immunotherapy
Li, S., Jin, Y., Wu, H., Yuan, H., & Zhao, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01765-4 · Cited by 14
PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance
Giardina, S. F., Valdambrini, E., Warren, J. D., & Barany, F. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210203110857 · Cited by 14
Sciaccotta, R., Gangemi, S., Penna, G., Giordano, L., Pioggia, G., & Allegra, A. (2024) · Antioxidants · doi:10.3390/antiox13040475 · Cited by 15
PROTAC Beyond Cancer- Exploring the New Therapeutic Potential of Proteolysis Targeting Chimeras
Bhole, R. P., Patil, S., Kapare, H. S., Chikhale, R. V., & Gurav, S. S. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266309968240621072550 · Cited by 15
Zaman, S. U., Pagare, P. P., Ma, H., Hoyle, R. G., Zhang, Y., & Li, J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00122b · Cited by 15
Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules
Delport, A., & Hewer, R. (2019) · Molecules · doi:10.3390/molecules24183272 · Cited by 14
MST and TRIC Technology to Reliably Study PROTAC Binary and Ternary Binding in Drug Development
Bartoschik, T., Zoephel, A., Rumpel, K., Ciulli, A., & Heffern, C. T. R. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_6 · Cited by 15
Pedrucci, F., Pappalardo, C., Marzaro, G., Ferri, N., Ferlin, A., & Toni, L. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126630 · Cited by 14
MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
Chang, M., Gao, F., Chen, J., Gnawali, G. R., & Wang, W. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0022 · Cited by 18
Chimera induced protein degradation: PROTACs and beyond
Yin, L., & Hu, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112494 · Cited by 14
Roatsch, M., Vogelmann, A., Herp, D., Jung, M., & Olsen, C. A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12416303.v1 · Cited by 14
Ding, B., Hu, J., Shou, B., Li, J., Yang, B., Cao, J., & Zhu, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00949 · Cited by 13
Programmable PROTAC delivery for precise and spatiotemporal protein degradation
Sheng, J., Ma, T., Wu, Y., & Wang, M. (2026) · Chemical Communications · doi:10.1039/d5cc05651a · Cited by 13
Targeting IRAK3 for Degradation to Enhance IL-12 Pro-inflammatory Cytokine Production
Rowley, A. M., Brown, B. S., Stofega, M. R., Hoh, H. Y., Mathew, R. S., Marin, V. L., Ding, R., McClure, R. A., Bittencourt, F. M., Chen, J., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00037 · Cited by 13
Wang, Y., Morisseau, C. H. P., Takamura, A., Wan, D., Li, D., Sidoli, S., Yang, J., Wolan, D. W., Hammock, B. D., & Kitamura, S. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00017 · Cited by 13
Single-domain antibody-based protein degrader for synucleinopathies
Jiang, Y., Lin, Y., Tetlow, A. M., Pan, R., Ji, C., Kong, X., Congdon, E. E., & Sigurdsson, E. M. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00730-y · Cited by 14
Development of natural product-based targeted protein degraders as anticancer agents
Chen, C., Feng, Y., Zhou, C., Liu, Z., Tang, Z., Zhang, Y., Li, T., Gu, C., & Chen, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107772 · Cited by 14
Wang, Y., Wang, M., Lan, M., Zhang, Y., Jiao, Y., Zhang, S., Yang, Y., Li, J., Wei, M., Cao, S., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01621 · Cited by 13
VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation
Mangano, K., Guenette, R. G., Hill, S., Li, S., Liu, J. J., Nadel, C. M., Archunan, S., Sadhukhan, A., Kapoor, R., Yang, S. W., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.02.002 · Cited by 14
Discovery of a Potent and Selective Protein Arginine Methyltransferase 5 (PRMT5) PROTAC Degrader
Zhong, Y., Kim, H., Qian, C., Xie, L., Chen, X., Xiong, Y., Hu, J., Chen, M., Guccione, E., Shen, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00198 · Cited by 15
PROTACs: The Future of Leukemia Therapeutics
Anwar, Z., Ali, M. S., Galvano, A., Perez, A., Mantia, M. L., Bukhari, I., & Świątczak, B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.851087 · Cited by 13
Lu, G., Tandang‐Silvas, M. R., Dawson, A., Dawson, T. J., & Groppe, J. C. (2018) · Bone · doi:10.1016/j.bone.2018.03.027 · Cited by 14
Evolving Rules for Protein Degradation? Insights from the Zinc Finger Degrome
Buhimschi, A. D., & Crews, C. M. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01307 · Cited by 12
Self-citationRecent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology
Mukhamejanova, Z., Tong, Y., Xiang, Q., Xu, F., & Pang, J. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200312112412 · Cited by 13
Recent Advances in PROTAC Technology Toward New Therapeutic Modalities
Yokoo, H., Naganuma, M., Oba, M., & Demizu, Y. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200828 · Cited by 14
TrypPROTACs Unlocking New Therapeutic Strategies for Chagas Disease
Gini, A. L. R., da Cunha, P. S. T., João, E. E., Chin, C. M., dos Santos, J. L., Serra, E. C., & Scarim, C. B. (2025) · Pharmaceuticals · doi:10.3390/ph18060919 · Cited by 12
A two-faced selectivity solution to target SMARCA2 for cancer therapy
Harling, J. D., & Tinworth, C. P. (2023) · Nature Communications · doi:10.1038/s41467-023-36238-0 · Cited by 12
Giardina, S. F., Valdambrini, E., Singh, P. K., Bacolod, M. D., Babu-Karunakaran, G., Peel, M. R., Warren, J. D., & Barany, F. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02097 · Cited by 12
Huber, A. D., Lin, W., Poudel, S., Miller, D. J., & Chen, T. (2024) · Structure · doi:10.1016/j.str.2024.09.016 · Cited by 12
Sflakidou, E., Adhikari, B., Siokatas, C., Wolf, E., & Sarli, V. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00405 · Cited by 12
PK/PD modeling of targeted protein degraders: Charting new waters and navigating the shallows
Haid, R. T. U., & Reichel, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104311 · Cited by 17
Advancing target validation with PROTAC technology
Spitz, M. L., Kashkush, A., & Benhamou, R. I. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2490248 · Cited by 12
PROTAC: A Novel Technology for Drug Development**
Li, J., & Liu, J. (2020) · ChemistrySelect · doi:10.1002/slct.202003162 · Cited by 13
Cobalt‐Catalyzed C(sp2)−O Bond Formation by Directing Group Assisted C−H Activation
Park, J.-H., & Son, J. (2022) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202200465 · Cited by 12
Pharmacological Modulation of Transcriptional Coregulators in Cancer
Bishop, T. R., Zhang, Y., & Erb, M. A. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.004 · Cited by 11
Rothweiler, E. M., Brennan, P. E., & Huber, K. (2022) · Biological Chemistry · doi:10.1515/hsz-2021-0396 · Cited by 12
PROTACting the kinome with covalent warheads
Chatterjee, D. R., Kapoor, S., Jain, M., Das, R., Chowdhury, M. G., & Shard, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103417 · Cited by 12
Chemically Induced Degradation of Native Proteins by Direct Recruitment to the 26S ProteasomePreprint
Balzarini, M., Gui, W., Jayalath, I. M., Schell, B.-B., Tong, J., & Kodadek, T. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.19.549534 · Cited by 12
Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed
Kanbar, K., Darzi, R. E., & Jaalouk, D. E. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1434002 · Cited by 17
Karpińska, K., Mehlich, D., Sabbasani, V. R., Łomiak, M., Torres‐Ayuso, P., Wróbel, K., Truong, V. N.-P., Serwa, R. A., Swenson, R. E., Brognard, J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00577 · Cited by 12
Extrapolating Lessons from Targeted Protein Degradation to Other Proximity-Inducing Drugs
Winter, G. E. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00191 · Cited by 13
A comprehensive primer and review of PROTACs and their In Silico design
Zattoni, J., Vottero, P., Carena, G., Uliveto, C., Pozzati, G., Morabito, B., Gitari, E., Tuszyński, J. A., & Aminpour, M. (2025) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2025.108687 · Cited by 14
Proteolysis‐Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research
Pan, M., Fu, Z., Hou, H., Yang, C., & Li, J. (2025) · Small Methods · doi:10.1002/smtd.202500402 · Cited by 13
Proteome-Wide Discovery of Degradable Proteins Using Bifunctional Molecules
Forrest, I., Conway, L. P., Gathmann, C., Jadhav, A. M., Chiu, T.-Y., Chaheine, C. M., Estrada, M. A., Shrestha, A., Sarris, K., Reitsma, J. M., et al. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c01594 · Cited by 12
Affecting RNA biology genome-wide by binding small molecules and chemically induced proximity
Baisden, J. T., Childs‐Disney, J. L., Ryan, L. S., & Disney, M. D. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.03.006 · Cited by 12
Mapping the energy landscape of PROTAC-mediated protein-protein interactions
Villegas, J. A., Vaid, T. M., Johnson, M. E., & Moore, T. W. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.02.049 · Cited by 11
Bifunctional robots inducing targeted protein degradation
Sobhia, M. E., Kumar, H., & Kumari, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115384 · Cited by 11
Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras
Hamilton, G., Stickler, S., & Rath, B. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230418114520 · Cited by 11
León, R. G., & Bassham, D. C. (2023) · Pest Management Science · doi:10.1002/ps.7741 · Cited by 10
Tanaka, T., Thomas, J. C., van Montfort, R., Miller, A., & Rabbitts, T. H. (2021) · Scientific Reports · doi:10.1038/s41598-021-81262-z · Cited by 11
Perspectives on the Development of First-in-Class Protein Degraders
Rambacher, K. M., Calabrese, M. F., & Yamaguchi, M. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0033 · Cited by 11
The chemical biology of ubiquitin
Burslem, G. M. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.130079 · Cited by 11
Self-citationWang, Y., Deng, S., & Xu, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0066 · Cited by 10
O’Hanlon, J. A., Gutsche, K., Müller, J. E., Prusty, N. R., Mirza, A. R., Roumeliotis, T. I., Yang, H., Stubbs, M., Hallett, S. T., Eing, L., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03024 · Cited by 11
Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2)
Valdivia, A., Vagadia, P. P., Guo, G., O’Brien, E., Matei, D. E., & Schiltz, G. E. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01859 · Cited by 10
p21-Activated Kinase 4 and Ischemic Acute Kidney Injury in Mice and Humans
Yu, H. C., Chung, B. H., Kim, Y., Lee, Y., Sim, H., Lee, S., Hwang, H. P., Yu, H. C., Jeon, S., Maeng, H., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000649 · Cited by 10
RetractedGu-liang, Y., Zhong, H., Xia, X., Qi, Z., Wang, C., & Li, S. (2021) · Food Science and Human Wellness · doi:10.1016/j.fshw.2021.11.001 · Cited by 10
Discovery of a Potent and Selective Degrader for USP7
Pei, Y., Fu, J., Shi, Y., Zhang, M., Luo, G., Luo, X., Song, N., Mi, T., Yang, Y., Li, J. X., et al. (2022) · Angewandte Chemie · doi:10.1002/ange.202204395 · Cited by 10
Dogheim, G. M., & Amralla, M. T. (2023) · Drug Development Research · doi:10.1002/ddr.22055 · Cited by 11
Zhao, C., Wang, H., Zhan, W., Lv, X., & Ma, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00079 · Cited by 9
Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs
Yao, R., Luo, T., & Wang, M. (2023) · ChemBioChem · doi:10.1002/cbic.202300413 · Cited by 9
EGFR degraders in non‐small‐cell lung cancer: Breakthrough and unresolved issue
Shen, J., Chen, L., Liu, J., Li, A., Zheng, L., Chen, S., & Li, Y. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14517 · Cited by 10
Investigating protein degradability through site-specific ubiquitin ligase recruitment
Shade, O., Ryan, A., Belsito, G., & Deiters, A. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00273c · Cited by 9
Research progress in bifunctional small molecules for cancer immunotherapy
Cheng, B., Li, H., Hong, Y., Zhou, Y., Chen, J., Shao, C., & Kong, Z. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117289 · Cited by 9
Targeting FOXP1 phase separation in small cell lung cancer mechanisms of chemotherapy resistance
Tang, Y., Niu, Y., Chen, Y., Zhou, X., Hu, Y., Sun, L., Xiong, Y., Xu, Y., Wang, Q., Wang, Y., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07804-7 · Cited by 9
Inganäs, E., Lavén, H., Caraballo, R., Klingegård, F., Eklund, M., Andersson, L., Hilgendorf, C., & Matsson, P. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01499 · Cited by 9
Reboud‐Ravaux, M. (2021) · Biologie Aujourd hui · doi:10.1051/jbio/2021007 · Cited by 10
The 17 th EFMC Short Course on Medicinal Chemistry on Small Molecule Protein Degraders
Ciulli, A., O’Connor, S., Chung, C., Hartung, I. V., Testa, A., Daniels, D. L., & Heitman, L. H. (2023) · ChemMedChem · doi:10.1002/cmdc.202300464 · Cited by 9
Yang, X., He, Y., Kim, R. D., Fleming, J. B., & Xie, H. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00782-2 · Cited by 10
Try Me: Promiscuous Inhibitors Still Allow for Selective Targeted Protein Degradation
Müller, M. P., & Rauh, D. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.01.004 · Cited by 9
Julio, A. R., Shikwana, F., Truong, C. C., Burton, N. R., Dominguez, E. R., Turmon, A. C., Cao, J. X., & Backus, K. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.30.564067 · Cited by 8
PROTAC-induced protein structural dynamics in targeted protein degradationPreprint
Wu, K. Y., Hung, T. I., & Chang, C. A. (2024) · eLife · doi:10.7554/elife.101127 · Cited by 8
Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation
Miao, J., & Zhang, Z. (2024) · ChemMedChem · doi:10.1002/cmdc.202300669 · Cited by 9
Ye, L., Wang, W., Li, H., Ji, Y., Le, X., & Xu, X. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241290733 · Cited by 8
Development of Dual Aurora‐A and Aurora‐B Degrading PROTACs for MYCN‐Amplified Neuroblastoma
Nelson, S. E., Tucker, J. R., Prado, M. G., Tierney, L. C., Quigley, S. L., Lumpkin, A. T., Dodd, C. J., Hasko, V., Howie, S. L., Aastha, A., et al. (2024) · ChemMedChem · doi:10.1002/cmdc.202400703 · Cited by 9
Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration
Jeong, S., Cha, J., Ahmed, W., Kim, J., Kim, M., Hong, K. T., Choi, W., Choi, S., Yoo, T. H., An, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202415626 · Cited by 9
Advances in MLKL-targeted inhibitors and PROTACs for necroptosis therapeutics
Dai, P., Xin, Y., Qin, X., Ma, H., & Zhuang, C. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118246 · Cited by 8
Martelly, W., Cook, R. L., Agu, C. V., Gushgari, L. R., Moreno, S., Kesiraju, S., Mohan, M., & Takulapalli, B. R. (2025) · Biomolecules · doi:10.3390/biom15060882 · Cited by 8
Targeting p53 activation: Recent therapeutic advances in cancer and diabetic macular edema
Wang, Z., Zhang, S., Mélita, I. L., & Zhao, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117909 · Cited by 10
Zheng, R., Prasad, A., Satyabola, D., Xu, Y., Roy, S., Yan, Y., Šulc, P., & Yan, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c04918 · Cited by 8
Bazzacco, A., Mercorelli, B., & Loregian, A. (2025) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaf046 · Cited by 11
Structural basis for DCAF2 as a novel E3 ligase for PROTAC-mediated targeted protein degradation
McMahon, E., Cioffi, A. G., Visperas, P. R., Lin, Y., Shaghafi, M. B., Daczkowski, C. M., Hermann, J. C., Everley, R. A., Neve, R. M., Erlanson, D. A., et al. (2025) · Structure · doi:10.1016/j.str.2025.09.006 · Cited by 11
PROTAC‐Based HDAC Degradation: A Paradigm Shift in Targeted Epigenetic Therapies
Himaja, A., Halder, D., Banerjee, S., Biswas, S., Adhikari, N., & Ghosh, B. (2025) · ChemMedChem · doi:10.1002/cmdc.202500203 · Cited by 9
PROTAC: A Novel Drug Delivery Technology for Targeting Proteins in Cancer Cells
Bala, R., Sindhu, R. K., Madaan, R., & Yadav, S. K. (2022) · Current Drug Discovery Technologies · doi:10.2174/1570163820666221031124612 · Cited by 8
Epigenetic markers and therapeutic targets for metastasis
Kravitz, C. J., Yan, Q., & Nguyen, D. X. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10109-y · Cited by 9
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
Li, P., Li, B., Yang, N., Xu, T., & Zheng, Z. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2262176 · Cited by 8
Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy
De, S., Sahu, R., Palei, S., & Nanda, L. N. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117875 · Cited by 9
Tomoshige, S., & Ishikawa, M. (2020) · Angewandte Chemie · doi:10.1002/ange.202004746 · Cited by 8
Reviewing the toolbox for degrader development in oncology
Cresser-Brown, J. O., Marsh, G. P., & Maple, H. J. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.04.009 · Cited by 8
COVID-19 Therapies: Protease Inhibitions and Novel Degrader Strategies
Reboud‐Ravaux, M., & Amri, C. E. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.892057 · Cited by 8
The rise of targeting chimeras (TACs): next-generation medicines that preempt cellular events
Hollingsworth, S. A., Johnson, S. A., Khakbaz, P., Meng, Y., Mouchlis, V. D., Pierce, O., Prytkova, V. D., Vik, E. S., Weiss, D. R., & Shanmugasundaram, V. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03104-z · Cited by 11
Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy
Ohoka, N. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.18-00113 · Cited by 8
Ciulli, A., & Hsia, O. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch9 · Cited by 8
Targeted Strategies for Degradation of Key Transmembrane Proteins in Cancer
Sakanyan, V. A., Iradyan, N., & de Sousa, R. A. (2023) · BioTech · doi:10.3390/biotech12030057 · Cited by 8
PROTAC-PatentDB: A PROTAC Patent Compound Dataset
Cai, H., Yao, G., Shi, Y., Zhang, T., & Yuanjia, H. (2025) · Scientific Data · doi:10.1038/s41597-025-06136-9 · Cited by 8
Modulation of IRAK enzymes as a therapeutic strategy against SARS-CoV-2 induced cytokine storm
Mahmoud, I. S., Jarrar, Y. B., & Febrimarsa, F. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01064-7 · Cited by 9
Metadata
- Authors
- Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M.
- Affiliations
- Yale University (US)
- Arvinas (United States) (US)
- Corresponding author
- Crews, Craig M.
- ORCID
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 25
- Issue
- 1
- Pages
- 78-87.e5
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- PMC
- PMC5777153
- OpenAlex
- W2767856718
- Cited by
- 923
- References
- 50
- Citations by year
- 2026: 104 · 2025: 133 · 2024: 147 · 2023: 104 · 2022: 110 · 2021: 110 · 2020: 109 · 2019: 72 · 2018: 29
- FWCI
- 23.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell chemical biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NCI (F99 CA212229-02, R50 CA211252-02)
- Leukemia and Lymphoma Society Career Development
- NIH (R35CA197589)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, protein degradation, E3 ubiquitin ligase, cereblon, VHL, protein-protein interaction, ternary complex stability, PROTAC design, undruggable proteins, ubiquitination, proteasome
- MeSH terms
- Humans, Drug Design, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Protein Kinase Inhibitors, Small Molecule Libraries, Ubiquitination, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
